Table 1 Baseline characteristics of the overall population.
All patients n = 76 | MICU survivors n = 40 | MICU non survivors n = 36 | P value | |
|---|---|---|---|---|
Patient characteristics | ||||
Age (years), mean ± SD | 62.95 ± 9.9 | 62.94 ± 9.7 | 62.96 ± 10.3 | 0.99 |
Males, n (%) | 69 (90.8) | 36 (90) | 33 (91.7) | 0.56 |
Period: before January 1, 2002 | 17 (22.4) | 10 (25) | 7 (19.4) | 0.36 |
Co-morbidities | ||||
Smoking, n (%) | 71 (95.9) | 39 (97.5) | 32 (94.1) | 0.43 |
CCI, mean ± SD [range] | 1.69 ± 1.54 | 1.63 ± 1.71 | 0.87 | |
CCI Low, n (%) | 13 (32.5) | 14 (35) | 0.83 | |
Mid-range, n (%) | 14 (35) | 11 (27.5) | ||
High, n (%) | 13 (32.5) | 11 (27.5) | ||
COPD, n (%) | 24 (32) | 12 (30) | 12 (33) | 0.42 |
Chronic respiratory failure, n (%) | 4 (5.3) | 3 (7.5) | 1 (2.7) | 0.37 |
Diabetes, n (%) | 9 (11.8) | 5 (12.5) | 4 (11.1) | 0.57 |
Non pulmonary neoplasm, n (%) | 16 (21) | 10 (25) | 6 (16,6) | 0.28 |
Lung cancer | ||||
NSCLC, n (%) | 49 (64.5) | 28 (70) | 21 (58.3) | 0.21 |
Squamous cell carcinoma, n (%) | 30/49 (61,2) | 18/29 (62.1) | 12/20 (60) | 0.56 |
Adenocarcinoma, n (%) | 14/49 (28.6) | 7/29 (24.1) | 7/20 (35) | 0.30 |
Undifferentiated carcinoma, n (%) | 2 (4.1) | 2/29 (6.9) | 0 | 0.34 |
SCLC, n (%) | 29 (38.2) | 14 (35) | 15 (41.7) | 0.35 |
Stage* | ||||
NSCLC IIIB, n (%) | 20/49 (40.8) | 10/28 (35.7) | 10/21 (47.6) | 0.29 |
NSCLC IV, n (%) | 29/49 (59.2) | 18/28 (64.3) | 11/21 (52.4) | 0.29 |
Localized SCLC, n (%) | 11/29 (37.9) | 6/14 (42.9) | 5/15 (33.3) | 0.44 |
Disseminated SCLC, n (%) | 18/29 (62.1) | 8/14 (57.1) | 10/15 (66.7) | 0.44 |
Metastasis, n (%) | 45 (59.2) | 24 (60) | 21 (58.3) | 0.53 |
Lung cancer treatment | ||||
Chemotherapy, n (%) | 43 (56.5) | 19 (47.5) | 24 (66.7) | 0.073 |
Radiotherapy, n (%) | 22 (28.9) | 8 (20) | 14 (38.9) | 0.05 |
Surgery, n (%) | 6 (7.9) | 2 (5) | 4 (11) | 0.28 |